Fig. 3: An hPSC-LO-based high-throughput chemical screen identifies three FDA-approved drug candidates that block SARS-CoV-2 entry.
From: Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
a, Primary screening results. The red line indicates a Z score of less than −2, which means the luminescent signal is lower than average − 2 × s.d. b–d, The chemical structures of imatinib (b), MPA (c) and QNHC (d). e–g, Efficacy and toxicity curves for imatinib (e), MPA (f) and QNHC (g). n = 3 biologically independent experiments. h, Immunofluorescent staining of luciferase+ cells in imatinib, MPA and QNHC-treated hPSC-LOs at 24 hpi (MOI = 0.01). Scale bars, 50 μm (main images) and 10 μm (insets). i, A scheme of the in vivo drug treatment. j, k, Immunostaining (j) and quantification (k) of hPSC-derived lung xenografts of mice treated with 400 mg kg−1 imatinib mesylate, 50 mg kg−1 MPA and 25 mg kg−1 QNHC at 24 hpi (1 × 104 FFUs). Scale bars, 100 μm (main images) and 10 μm (insets). n = 6 xenografts for each group. ***P = 5.54 × 10−6; ***P = 5.19 × 10−6; ***P = 1.66 × 10−5 (***P < 0.001). The data were analysed by an unpaired two-tailed Student’s t-test and are shown as mean ± s.d. The data are representative of at least three independent experiments.